HC Wainwright Reiterates Buy Rating for Gain Therapeutics (NASDAQ:GANX)

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $8.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 294.09% from the stock’s previous close.

Several other research firms have also commented on GANX. Weiss Ratings lowered Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 9th. Wall Street Zen raised Gain Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, June 21st. BTIG Research restated a “buy” rating and issued a $5.00 price target on shares of Gain Therapeutics in a report on Tuesday. Roth Mkm reaffirmed a “buy” rating on shares of Gain Therapeutics in a research note on Tuesday, May 12th. Finally, Oppenheimer reiterated an “outperform” rating on shares of Gain Therapeutics in a report on Wednesday, May 27th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Gain Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $7.50.

Gain Therapeutics Stock Performance

Shares of GANX opened at $2.03 on Wednesday. Gain Therapeutics has a 1 year low of $1.41 and a 1 year high of $4.34. The company’s 50 day simple moving average is $1.82 and its 200 day simple moving average is $2.15. The company has a market capitalization of $86.58 million, a price-to-earnings ratio of -3.50 and a beta of 0.16. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.69 and a current ratio of 4.69.

Gain Therapeutics (NASDAQ:GANX) last released its earnings results on Monday, May 11th. The company reported ($0.13) EPS for the quarter, hitting the consensus estimate of ($0.13). During the same quarter in the previous year, the firm earned ($0.16) earnings per share. On average, sell-side analysts predict that Gain Therapeutics will post -0.54 EPS for the current year.

Institutional Investors Weigh In On Gain Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Apollon Wealth Management LLC increased its stake in Gain Therapeutics by 33.7% during the first quarter. Apollon Wealth Management LLC now owns 26,500 shares of the company’s stock worth $51,000 after acquiring an additional 6,675 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Gain Therapeutics by 2.9% in the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock valued at $523,000 after purchasing an additional 8,251 shares in the last quarter. Sprott Inc. purchased a new stake in shares of Gain Therapeutics during the 4th quarter worth about $39,000. Commonwealth Equity Services LLC purchased a new stake in shares of Gain Therapeutics during the 4th quarter worth about $41,000. Finally, Millennium Management LLC acquired a new stake in Gain Therapeutics during the 4th quarter worth approximately $45,000. Hedge funds and other institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.